Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S‑9‑(2‑hydroxypropyl)adenine is a synthetic purine derivative belonging to the class of organic compounds known as 6‑aminopurines. It is the S-isomer of 1-(6-amino-purin‑9‑yl)-propan‑2‑ol and has been used primarily as an intermediate or impurity in the synthesis of antiviral acyclic nucleoside phosphonates such as tenofovir. The compound itself has been described as an inhibitor of adenosine deaminase and may act on viral thymidine kinase, but it is not approved for clinical use and remains experimental[1][3][6]. Its mechanism involves potential interaction with viral enzymes involved in nucleotide metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-9-(2-hydroxypropyl)adenine.